Relevant bibliographies by topics / Tramadol hydrochloride

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Tramadol hydrochloride'

Author: Grafiati
Published: 4 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tramadol hydrochloride.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tramadol hydrochloride"

1

Olson, Nancy Z., Abraham Sunshine, Edward OʼNeill, Juana Rivera, and Fredrick L. Minn. "Tramadol Hydrochloride." Clinical Journal of Pain 7, no. 1 (1991): 55. http://dx.doi.org/10.1097/00002508-199103000-00069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Reanmongkol, Wantana, Nattha Kaewnopparat, and Chaveewan Ratanajamit. "Physicochemical properties, in vitro release and in vivo evaluation of tramadol hydrochloride rectal suppository and rectal gel." Asian Biomedicine 5, no. 2 (2011): 269–75. http://dx.doi.org/10.5372/1905-7415.0502.037.

Full text
Abstract:
Abstract Background: Tramadol is a centrally acting analgesic drug. Rectal administration of tramadol is useful in the treatment of post-operative pain or malignant pain in cases where it cannot be administered orally. In Thailand, tramadol is available only as a capsule for oral use and as a solution for injection. Objective: Develop tramadol hydrochloride rectal suppositories and rectal gel preparations. Methods: Tramadol rectal suppository and rectal gel were prepared. Physicochemical properties (viscosity, gel strength, mucoadhesive force) and the in vitro release of tramadol hydrochloride were investigated from different bases (Witepsol H15, polyethylene glycol, poloxamer, and hydroxyethylcellulose). The analgesic activity of rectal tramadol hydrochloride using the hot plate test was evaluated in rats. Results: Tramadol hydrochloride rectal gel using poloxamer was more mucoadhesive to the rectal mucous membrane than was the gel with the hydroxyethylcellulose base. Tramadol hydrochloride was released rapidly in vitro from both the Witepsol H15 and polyethylene glycol bases. It was completely released from the polyethylene glycol suppository base within 15 minutes. The amount of tramadol hydrochloride release from the Witepsol H15 suppository base was about 93% at 120 minutes. When using poloxamer or hydroxyethylcellulose as a rectal base, tramadol hydrochloride was released from both bases rapidly and completely released within 15 minutes. Administration of a tramadol hydrochloride suppository in rats exhibited a more pronounced analgesic effect with the polyethylene glycol base than with the Witepsol H15-based suppositories. The rectal gel had a less pronounced analgesic effect when made with the hydroxyethylcellulose base than with the poloxamer base. Conclusion: Tramadol hydrochloride suppositories and rectal gels with different bases showed rapid and almost complete drug release from the bases, prolonging the latency of a nociceptive response in in vivo experiments.
APA, Harvard, Vancouver, ISO, and other styles
3

Bahulekar, Ashutosh. "COMPARISON OF TRAMADOL HYDROCHLORIDE AND DEXMEDETOMIDINE FOR THE MANAGEMENT OF INTRA-OPERATIVE SHIVERING IN SUBJECTS UNDERGOING SPINAL ANAESTHESIA." Journal of Medical pharmaceutical and allied sciences 10, no. 3 (2021): 3061–63. http://dx.doi.org/10.22270/jmpas.v10i3.1229.

Full text
Abstract:
In the management of post-spinal shivering, pharmacological approaches involving a range of medications. in our research, we compared two readily available and effective medications, dexmedetomidine and tramadol hydrochloride, intravenously administered for treating shivering in subjects who received spinal anaethesia for different surgical interventions in the search for a more secure and efficacious medication. under spinal anaethesia, a comparison of tramadol hydrochloride and dexmedetomidine for the prevention of intra-operative shivering. a prospective, randomized study of 40 american society of anesthesiologists stage i and ii subjects of either sex, aged 21 to 65 years, who were scheduled for various surgical interventions under spinal anaethesia was performed. dexmedetomidine 1g/kg or tramadol hydrochloride 1mg/kg were given as a slow IV infusion over 5 minutes to the subjects, who were divided into two categories of 40 subjects each. shivering severity, onset, time to manage shivering, recurrence, and adverse results were all monitored at regular intervals. dexmedetomidine took 205.10 + 18.6 seconds to stop shivering, while tramadol hydrochloride took 413.24 + 16.45 seconds. only the tramadol hydrochloride category experienced nausea and vomiting. the sedation profiles of the two medications were similar. shivering caused by post-spinal anaethesia can be effectively managed with dexmedetomidine (1 g/kg) and tramadol hydrochloride (1 mg/kg). as compared to tramadol hydrochloride, dexmedetomidine takes less time to control shivering. it has an advantage over tramadol hydrochloride in that it has less side results such as nausea and vomiting.
APA, Harvard, Vancouver, ISO, and other styles
4

Liu, Ping, Liang Sun, Jian Zhang, and Rui Chen Guo. "An Evaluation of the Potential for Pharmacokinetic Interaction between Tramadol and Cytochrome P450 2D6 Inhibitor Promethazine." Advanced Materials Research 989-994 (July 2014): 1041–43. http://dx.doi.org/10.4028/www.scientific.net/amr.989-994.1041.

Full text
Abstract:
In this single-center, randomized, open-label, 3-way crossover study, subjects received each of the following: a single dose of Tramadol Hydrochloride Injection (THI) 35 mg, a single dose of Promethazine Hydrochloride Injection (PHI) 45 mg, and single dose of Compound Tramadol Hydrochloride Injection (CTHI) 80mg. Blood was collected and plasma was analyzed for the pharmacokinetic parameters (maximum plasma concentration [Cmax], time to Cmax [Tmax], area under the plasma concentration-time curve, plasma elimination half-life, clearance, and apparent volume of distribution) of Tramadol and Promethazine. In general, several pharmacokinetic interactions were observed between Tramadol and Promethazine in the present study.
APA, Harvard, Vancouver, ISO, and other styles
5

KUMAR, TATAPUDI HEMANT. "Simultaneous Quantitation Tramadol Hydrochloride and Diclofenac Sodium by RP-HPLC in Fixed-dose Combination(FDC)." ASM Science Journal 19 (December 24, 2024): 1–8. https://doi.org/10.32802/asmscj.2023.1587.

Full text
Abstract:
The concurrent detection of tramadol hydrochloride and diclofenac sodium in their mixed dosage form as tablet was developed and validated using a simple, accurate, inexpensive, and precise RP-HPLC approach with a UV-Visible detector. Enable C18 G analytical column (250 x 4.6 mm, i.d., 5 μm) was used for the separation. The mobile phase was made of a mixture of 80 volumes of acetonitrile and 20 volumes of 1 % v/v glacial acetic acid. Isocratic elution was utilised at a flow rate of 1 mL/min during the chromatographic process. Tramadol hydrochloride and diclofenac sodium were identified at UV detector wavelength of 264 nm and established linear calibration curves with concentration ranges of 20–100 μg/ml and 15–75 μg/ml, respectively. Tramadol hydrochloride had recoveries of 99.62–99.86% and diclofenac sodium had a recoveries of 99.48-100.22%. The approach was validated in the context of the International Conference of Harmonisation's requirements for accuracy, precision, specificity, robustness, limits of detection and quantification. The precision studies for both drugs were found to be < 2% (%RSD). The limits of detection for tramadol hydrochloride and diclofenac sodium were found to be 0.12 μg/ml and 0.07 μg/ml, respectively. The limits of quantification for tramadol hydrochloride and diclofenac sodium were found to be 0.45 μg/ml and 0.21 μg/ml, respectively. Both tramadol hydrochloride and diclofenac sodium, two commercial pharmaceutical drugs, were effectively analysed using high-performance liquid chromatography using the described approach.
APA, Harvard, Vancouver, ISO, and other styles
6

Jahan, B. Ishrat, Nikhileshwar Palakurthi, Mrunalini Alugolu, and Khaliq Ahmed Md. "Comparative Efficacy of Nalbuphine Hydrochloride vs. Tramadol Hydrochloride for Post-Operative Analgesia in Orthopaedic Surgeries: A Double-Blind Randomized Control Study." Journal of Neonatal Surgery 14, no. 8S (2025): 1–5. https://doi.org/10.52783/jns.v14.2486.

Full text
Abstract:
Background: Effective postoperative analgesia is crucial for early mobilization and recovery in orthopaedic surgeries. This study compares the efficacy and safety of Nalbuphine Hydrochloride and Tramadol Hydrochloride for postoperative pain management in patients undergoing orthopaedic procedures. Methods: A double-blind, randomized controlled trial was conducted involving 100 patients who underwent various orthopaedic surgeries. Patients were randomly assigned to receive either Nalbuphine Hydrochloride or Tramadol Hydrochloride postoperatively. The primary outcomes measured were pain intensity using the Visual Analogue Scale (VAS) at specific time intervals and adverse effects. Secondary outcomes included hemodynamic stability and the need for additional analgesic doses. Results: Patients receiving Nalbuphine reported significantly lower VAS scores at 30 minutes (1.80 ± 0.50) and 540 minutes (2.00 ± 0.29) post-operation compared to those receiving Tramadol (2.21 ± 0.41 and 2.38 ± 0.58, respectively; p<0.01). Nalbuphine also demonstrated fewer adverse effects such as nausea and vomiting. Hemodynamic parameters were stable and comparable between the two groups. Conclusion: Nalbuphine Hydrochloride provides superior analgesia with fewer adverse effects compared to Tramadol Hydrochloride in the postoperative management of orthopaedic patients, making it a potentially preferable option for pain control in this population.
APA, Harvard, Vancouver, ISO, and other styles
7

Kaduk, James A., Kai Zhong, Amy M. Gindhart, and Thomas N. Blanton. "Crystal structure of tramadol hydrochloride, C16H26NO2Cl." Powder Diffraction 30, no. 3 (2015): 242–49. http://dx.doi.org/10.1017/s088571561500041x.

Full text
Abstract:
The crystal structure of tramadol hydrochloride has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Tramadol hydrochloride crystallizes in space group Cc (#9) with a = 9.680 72(2), b = 19.191 27(4), c = 9.285 94(1) Å, β = 100.5923(1)°, V = 1695.795(5) Å3, and Z = 4. The solid-state conformation of the cation differs from the minimum-energy conformation of the tramadol cation in water, and from the conformation observed in the benzoic acid adduct of tramadol hydrochloride. N–H···Cl and O–H···Cl hydrogen bonds form a zigzag chain with graph set C1,2(8) along the c-axis. C–H···O hydrogen bonds also contribute to the crystal energy. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™.
APA, Harvard, Vancouver, ISO, and other styles
8

Sharma, Rajesh, Mukesh C. Sharma, and Gaurav Vijaywargiya. "SIMULTANEOUS DETERMINATION OF PARACETAMOL, ACECLOFENAC AND TRAMADOL HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC METHOD." INDIAN DRUGS 58, no. 01 (2021): 35–40. http://dx.doi.org/10.53879/id.58.01.11617.

Full text
Abstract:
Chromatographic separation of paracetamol, aceclofenac and tramadol hydrochloride was performed on a Chromatopak C-18 column (25 cm x 4.6mm i.d. x 5µm) as stationary phase with a mobile phase composed of phosphate buffer pH 7.0: acetonitrile (65:35 V/V), pH 7.0 (adjusted with triethylamine) at flow rate of 1mL/min. Detection was carried out at 265 nm. The retention times of paracetamol, aceclofenac and Tramadol hydrochloride were found to be 2.7, 4.5 and 6.0 min, respectively. The proposed method was validated for linearity, accuracy, precision, LOD and LOQ. The method was found to be accurate, precise, specific, robust, and linear for the determination of paracetamol, aceclofenac and tramadol hydrochloride in pharmaceutical dosage form.
APA, Harvard, Vancouver, ISO, and other styles
9

Mason, Barbara J., and Kate H. Blackburn. "Possible Serotonin Syndrome Associated with Tramadol and Sertraline Coadministration." Annals of Pharmacotherapy 31, no. 2 (1997): 175–77. http://dx.doi.org/10.1177/106002809703100208.

Full text
Abstract:
Objective To report a possible case of serotonin syndrome associated with coadministration of tramadol hydrochloride and sertraline hydrochloride. Case Summary A 42-year-old woman developed atypical chest pain, sinus tachycardia, confusion, psychosis, sundowning, agitation, diaphoresis, and tremor. She was taking multiple medications, including tramadol and sertraline. The tramadol dosage had recently been increased, resulting in what was believed to be a serotonergic syndrome. Discussion Serotonin syndrome is a toxic hyperserotonergic state that develops soon after initiation or dosage increments of the offending agent. Patients may differ in their susceptibility to the development of serotonin syndrome. The (+) enantiomer of tramadol inhibits serotonin uptake. Tramadol is metabolized to an active metabolite, Ml, by the CYP2D6 enzyme. If this metabolite has less serotonergic activity than tramadol, inhibition of CYP2D6 by sertraline could have been a factor in the interaction. Conclusions Clinicians should be aware of the potential for serotonin syndrome with concomitant administration of sertraline and tramadol.
APA, Harvard, Vancouver, ISO, and other styles
10

Dangi, Nanci, Sunil K. Jain, Vivek Jain, Rupesh K. Jain, and Pushpendra Kumar Khangar. "Development and Characterization of Tramadol Hydrochloride Rectal Suppository." Asian Journal of Dental and Health Sciences 2, no. 3 (2022): 19–22. http://dx.doi.org/10.22270/ajdhs.v2i3.29.

Full text
Abstract:
Tramadol is a centrally acting analgesic drug. Rectal administration of tramadol is useful in the treatment of post-operative pain or malignant pain in cases where it cannot be administered orally. Rectal suppositories of tramadol hydrochloride were prepared using different bases and polymers and the effect of different additives on in vitro release of tramadol hydrochloride was studied. The agar-based suppositories were non-disintegrating/non-dissolving. All the prepared suppositories were evaluated for various physical parameters like weight variation, drug content and hardness. In vitro release study was performed by USP type I apparatus. Addition of 10% w/w propylene glycol accelerates the release of tramadol hydrochloride significantly (P<0.05) as in A1, which may be due to decrease in the gel matrix of agar. In formulation A2, A3 Addition of HPMC (1%, 3% w/w) and in formulation A3 and A4 addition of PVP (1%, 3% w/w) retards the release significantly (P<0.05), which may be due to increase in the viscosity and gel strength of the polymer matrix. Hence, PVP, HPMC and similar polymers in higher concentration can be used to formulate sustained released suppositories. The sustained release suppositories can be prepared by addition of PVP, HPMC in agar-based suppositories. Keywords: Tramadol, Rectal suppositories, PVP, HPMC, Agar.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tramadol hydrochloride"

1

Bernardo, Naíssa Prévide. "Análise estereosseletiva do cloridrato de cis-tramadol e de suas impurezas em matéria-prima e formulação farmacêutica." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/60/60134/tde-10122008-222618/.

Full text
Abstract:
O cloridrato de tramadol, analgésico sintético de ação central, possui dois centros quirais: o isômero cis é ativo e o isômero trans é uma impureza de processo. Ambos os enantiômeros do cloridrato de cis-tramadol contribuem para o efeito analgésico, mas através de mecanismos diferentes, complementares e interativos farmacologicamente. Os dois isômeros do cis-tramadol apresentam efeitos terapêuticos, e a presença de impurezas, incluindo os isômeros trans - decorrentes do processo de síntese ou devido à decomposição - podem comprometer a qualidade do produto comercializado. Assim, este trabalho teve como objetivo desenvolver e validar metodologia estereosseletiva para análise do cloridrato de cis-tramadol e das possíveis impurezas quirais ou não na matéria-prima e formulações farmacêuticas. Para a separação e quantificação dos enantiômeros do cloridrato de cis-tramadol e das impurezas trans-tramadol, 1,2-olefina e 1,6-olefina, foi utilizada a coluna Chiralcel® OD-H, fase móvel constituída por hexano (60% e 100% de n-hexano, 1:1, v/v):isopropanol:dietilamina:ácido trifluoracético (99,5:0,5:0,3:0,1, v/v/v/v), na vazão de 0,7 mL min-1 e detecção em 274 nm. A coluna Chiralpak® AD fase móvel constituída por hexano (60% de n-hexano):etanol absoluto:dietilamina (95:5:0,1, v/v/v), na vazão de 1,0 mL min-1 e o comprimento de onda para detecção dos compostos foi de 228 nm foi utilizada para a separação e quantificação das impurezas O-desmetiltramadol, N-desmetiltramadol e tramadol N-óxido. Os métodos desenvolvidos foram devidamente validados através dos parâmetros seletividade, linearidade, precisão, exatidão, intervalo, limite de detecção e limite de quantificação. Os resultados obtidos na validação mostraram que os métodos são adequados para a determinação do cis-tramadol e de suas impurezas na matéria prima e na formulação farmacêutica.<br>Tramadol hydrochloride is a centrally acting analgesic with two chiral centers; the cis isomer is the active drug and the trans isomer is a process impurity. Both enantiomers of cis-tramadol hydrochloride contribute to the analgesic effect through different, but complementary and interactive pharmacological mechanisms. Although both isomers of cis-tramadol hydrochloride show therapeutic effects, the presence of impurities, originated from the synthesis process or due to degradation, can compromise the quality of the marketed product. The aim of this present work was the development and validation of a stereosselective methodology for the analysis of the drug cis-tramadol hydrochloride and the possible chiral or non-chiral impurities in raw materials and pharmaceutical formulations. The separation and quantitation of cis-tramadol enantiomers and the impurities trans-tramadol, 1,2-olefin and 1,6-olefin were carried out using a Chiralcel® OD-H column, mobile phase of hexane (60% and 100% of n-hexane, 1:1, v/v):2-propanol:diethylamine:trifluoroacetic acid (99,5:0,5:0,3:0,1, v/v/v/v) at a flow rate of 0,7 mL min-1 and detection at 274 nm. For the separation and quantitation of the impurities O-desmethyltramadol, N-desmethyltramadol and tramadol N-oxide, a Chiralpak® AD column was used with a mobile phase of hexane (60% of n-hexane):ethanol absolute: diethylamine (95:5:0,1, v/v/v) at a flow rate of 1,0 mL min-1 and detection at 228 nm. The methods were validated using the parameters selectivity, linearity, precision, accuracy, range, detection limit and quantitation limit. The results obtained show that the methods are suitable for the analysis of cis-tramadol and its impurities in raw material and pharmaceutical formulation.
APA, Harvard, Vancouver, ISO, and other styles
2

Kubíčková, Alena. "Studium lisovatelnosti přímo lisovatelných tabletovin s tramadol hydrochloridem." Master's thesis, 2015. http://www.nusl.cz/ntk/nusl-332821.

Full text
Abstract:
This thesis evaluates and compares compressibility of directly compressible tableting materials for the preparation of hydrophilic gel matrix tablets containing tramadol hydrochloride. Prosolv® SMCC 90 and Disintequik™ MCC 25 were used as the dry binders. Hypromelloses Methocel™ Premium K4M and Methocel™ Premium K100M were used in concentrations of 30 % and 50 %. Magnesium stearate was used as the lubricant in concentration of 1%. The compressibility was evaluated by means of the energy profile of the compression process and determination of tensile strength of the tablets. The tableting materials with Prosolv® SMCC 90 exhibited the higher values of the total energy of compression than those with Disintequik™ MCC 25 at the same compression forces, tramadol decreased these values slightly. The tableting materials with Disintequik™ MCC 25 exhibited higher values of the total energy of compression in 50% concentration of both Methocels™ . In the case of Prosolv® SMCC 90 the values of plasticity were higher than at tableting materials with Disintequik™ MCC 25, particularly in 30% concentration of both types of Methocel™ . Tramadol decreased the plasticity slightly. The tableting materials with Prosolv® SMCC 90 provided stronger tablets. Tramadol decreased the strength of tablets and the strength values...
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Tramadol hydrochloride"

1

Govind, Jayantilal. "Tramadol Hydrochloride." In Encyclopedia of Pain. Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-28753-4_4551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Papich, Mark G. "Tramadol Hydrochloride." In Saunders Handbook of Veterinary Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00564-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smyj, Robert, Xiao-Ping Wang, and Feixue Han. "Tramadol Hydrochloride." In Profiles of Drug Substances, Excipients and Related Methodology. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-407691-4.00011-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Tramadol Hydrochloride." In ASHP® Injectable Drug Information™. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.385.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Papich, Mark G. "Tramadol Hydrochloride." In Papich Handbook of Veterinary Drugs. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-323-70957-6.00544-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"TraMADol Hydrochloride." In ASHP® Injectable Drug Information™. ASHP, 2024. https://doi.org/10.37573/9781585287444.402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jew, Rita K., Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes. "Tramadol Hydrochloride Suspension 5 mg/mL." In Extemporaneous Formulations. ASHP, 2022. http://dx.doi.org/10.37573/9781585286522.175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jew, Rita K., Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes. "Tramadol Hydrochloride Suspension 10 mg/mL." In Extemporaneous Formulations. ASHP, 2022. http://dx.doi.org/10.37573/9781585286522.176.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

B., Raja Narender, and T. Gayathri. "Design and Evaluation of Oro-Dispersible Tablets of Tramadol Hydrochloride." In Advanced Concepts in Pharmaceutical Research Vol. 9. B P International, 2024. http://dx.doi.org/10.9734/bpi/acpr/v9/3764g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jew, Rita K., Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes. "Tramadol Hydrochloride 7.5 mg/mL and Acetaminophen 65 mg/mL Suspension." In Extemporaneous Formulations. ASHP, 2022. http://dx.doi.org/10.37573/9781585286522.177.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tramadol hydrochloride"

1

Al-Khafaji, Inas Hasan, Ameen Waleed Qassim, and Mustafa F. Mohammed. "Development of an HPLC method for the determination of tramadol hydrochloride using ZIC-HILIC columns." In 4TH INTERNATIONAL CONFERENCE ON INNOVATION IN IOT, ROBOTICS AND AUTOMATION (IIRA 4.0). AIP Publishing, 2025. https://doi.org/10.1063/5.0254791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Arora, Rahul D. "Inpatient pharmacologic management of malignant bowel obstruction." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685360.

Full text
Abstract:
Background: Management of life threatening complications encountered in Advanced Cancer is an important domain of Palliative Oncology. Malignant Bowel Obstruction is usually an indicator of poor prognosis in Advanced cancer. It is usually associated with malignancies in the gastrointestinal tract or those outside the gastrointestinal tract (gynaecological malignancies). MBO can also occur with primary peritoneal as well as secondary peritoneal malignancies. Diagnostic criteria for MBO include Clinical evidence of bowel obstruction, obstruction distal to the Ligament of Treitz, presence of primary intraabdominal or extra abdominal cancer with peritoneal involvement. Materials: Detailed below are two cases of Malignant Bowel obstruction managed with Conservative inpatient nonoperative management with discussion of the proposed pharmacological protocol for the same. Case Details: A 45 year old Postmenopausal female diagnosed as carcinoma ovary stage iiic with left lower limb Deep Venous Thrombosis post multiple lines of chemotherapy including Paclitaxel plus Carboplatin, Etoposide, Tamoxifen and Liposomal Doxorubin, Malignant pleural effusion post thoracentesis was seen in the wards. A 31 year old Female a known case of moderately differentiated carcinoma colon with transmural infiltration and serosal seeding along with omental deposits with hepatic metastasis was seen in the casualty with signs of Multiple episodes of bilious vomiting with colicky abdominal pain and diagnosed to have malignant bowel obstruction on clinic radiological evaluation. Both these patients were provided non operative management of malignant bowel obstruction, were kept nil per oral, nasogastric decompression was performed with ryles tube insertion, antisecretory medication Inj Octreotide 100 ug three times daily, Anti Edema measures Inj Dexamethasone 8 mg intravrenous three times daily, Anti spasmodic and anti secretory medication Inj Hyoscine Butyl bromide 10 mg three times daily, inj Metronidazole 500 mg intravenous three times daily and Pain medication Inj Tramadol hydrochloride 50 mg intravenous in 100 ml of normal saline three times daily. Both these patients developed hyperglycemia which was managed with human regular insulin prescribed as per the sliding scale. Results: Ryles tube aspirate showed a decreasing trend and both the Patients achieved clinical resolution of symptoms underwent deintubation on Day 10 and Day 13 respectively and were taking oral feeds at the time of discharge. They were prescribed pharmacologic management of adhesive bowel obstruction consisting of Tab activated Dimethicone 40 mg three times daily, Tab Lactobacillus one tablet three times daily and Polyethylene glycol one satchet upto three times daily for 15 days at the time of discharge. Results: Resolution of symptoms can be achieved by providing non operative pharmacological management outlined above which consists of adequate hydration, parenteral nutrition when indicated, antibiotics, decongestive anti edema measures, anti spasmodic and anti secretory medication. Conclusion: Management of Hyperglycemia induced by Octreotide and Dexamethasone requires Insulin therapy. Optimum Duration, dosage and route of administration of Octreotide in management of Malignant Bowel Obstruction needs to be evaluated further.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tramadol hydrochloride' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography